ENDV - Endonovo Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0101
-0.0001 (-0.98%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.0102
Open0.0117
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0101 - 0.0117
52 Week Range0.0090 - 0.0661
Volume3,023,200
Avg. Volume6,688,203
Market Cap7.685M
Beta (3Y Monthly)2.37
PE Ratio (TTM)N/A
EPS (TTM)-0.0320
Earnings DateAug 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    Endonovo Therapeutics Announces Second Quarter Results

    LOS ANGELES, Aug. 13, 2019 -- via NetworkWire – Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announces financial and operating results for the.

  • GlobeNewswire

    Endonovo Therapeutics Inc. Featured in Exclusive NetworkNewsWire Broadcast

    NEW YORK, July 22, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Endonovo Therapeutics Inc. (ENDV), an innovative biotechnology company and commercial-stage developer of noninvasive Electroceutical™ therapeutic devices, today announces the broadcast of its exclusive audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community. Alan Collier, chairman and CEO of Endonovo Therapeutics, joins NNW host Stuart Smith for an in-depth discussion on the company’s flagship product, the SofPulse® Electroceutical™ Therapy device that many medical experts see as a potential solution to the nation’s opioid crisis. Described as an easy-to-place, non-invasive device that delivers targeted pulsed electromagnetic frequencies (tPEMF) to enhance post-surgical recovery, SofPulse has been cleared by the U.S. Federal Drug Administration (“FDA”) for the safe, palliative treatment of post-operative pain and to reduce edema (swelling).

  • GlobeNewswire

    Endonovo Therapeutics Appoints Dr. Peter Novak to its Scientific Advisory Board

    WOODLAND HILLS, Calif., July 15, 2019 -- via NetworkWire -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of noninvasive.

  • GlobeNewswire

    Endonovo Therapeutics Appoints Dr. Steven Levin of Johns Hopkins University to Its Scientific Advisory Board

    WOODLAND HILLS, Calif., June 21, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Endonovo Therapeutics, Inc. (ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, today announces the appointment of Steven Levin, M.D., to its scientific advisory board. Dr. Levin will work with the Endonovo team to facilitate the introduction of SofPulse® to healthcare facilities and further develop the Electroceutical™ devices pipeline. "Dr. Levin's vast experience with novel therapies in the anesthesiology and pain management field, as well as his strong research interest to improve clinical practice in pain management, will be valuable scientific additions to Endonovo," said Alan Collier, CEO, Endonovo Therapeutics.

  • GlobeNewswire

    Endonovo Therapeutics Announces National Rollout of SofPulse® Post-Operative Opioid Alternative into Hospitals

    WOODLAND HILLS, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Endonovo Therapeutics, Inc. (ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, announced today its initial plans and strategy for a national rollout of its SofPulse® targeted pulsed electromagnetic field (tPEMF) therapy device to hospitals throughout the United States. The Company has recently signed agreements with six master distributors and has hired approximately 40 sales associates. Endonovo’s plan is to have 300 sales representatives and be in the evaluation stage with 600 hospitals within the next 18 months.

  • GlobeNewswire

    Coverage Initiated for Endonovo Therapeutics via NetworkNewsWire

    NEW YORK, May 29, 2019 -- via NetworkWire -- Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company developing a bioelectronic approach to regenerative.

  • GlobeNewswire

    Endonovo Therapeutics and Veterans Healthcare Supply Solutions Announce Distribution Agreement

    Los Angeles, CA, May 21, 2019 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) and Veterans Healthcare Supply Solutions Inc. (VHSS) today announced a long-term agreement.

  • GlobeNewswire

    Endonovo Therapeutics Appoints Dr. Roc Alan McCarthy as a Scientific Advisory Board Member

    Los Angeles, CA , May 09, 2019 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, that Roc Alan McCarthy, D.O. will be joining the company as a Scientific Advisory.

  • GlobeNewswire

    Endonovo Therapeutics Announces Steven Ford as V.P. Marketing

    Los Angeles, CA, May 07, 2019 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, Steven Ford will be joining the company as Vice President of Marketing. In his.

  • GlobeNewswire

    Endonovo Therapeutics Hires David Clark as Vice President of Sales

    Los Angeles, May 03, 2019 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced veteran sales leader David Clark joined as Endonovo’s Vice President of Sales. In his.

  • GlobeNewswire

    Endonovo Therapeutics Hires Nevena Zubcevik of Harvard Medical School as Chief Medical Officer

    Endonovo Therapeutics, Inc. (ENDV), today announced the appointment of Nevena Zubcevik, DO, MSPT, ATC as its chief medical officer starting July 1, 2019. In her new role, Dr. Zubcevik will be in charge of medical and clinical strategy, including development and regulatory matters and new business development. Dr. Zubcevik has over 24 years experience in the medical field, 17 of which are in clinical development, and is a licensed physician and educator.

  • GlobeNewswire

    Endonovo Therapeutics Provides Corporate Update

    Endonovo Therapeutics, Inc. (ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, today announced a corporate update and business plan for the remainder of 2019. Revenue projections for the first quarter ended March 31, 2019 are expected to increase by roughly 80% over the same quarter last year. Alan Collier, Endonovo’s Chief Executive Officer, stated “I am pleased to announce Endonovo continues to execute our business plan and strategy implemented after acquiring the PEMF assets and technology.

  • GlobeNewswire

    Endonovo Therapeutics Announces Partnership with Second Hospital

    LOS ANGELES, CA , March 29, 2019 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced an agreement with a nationally recognized hospital.

  • GlobeNewswire

    Endonovo Therapeutics Granted Trademarks for WoundPulse and OrthoHalo

    LOS ANGELES, CA, March 22, 2019 -- March 22, 2019 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive.

  • GlobeNewswire

    Endonovo Therapeutics Partners with SunMED Medical Systems

    LOS ANGELES, CA, March 20, 2019 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), Alan Collier, Endonovo’s Chief Executive Officer, stated "We are.

  • GlobeNewswire

    Endonovo Therapeutics Files Lawsuit against KVP International Inc., Orthocor Medical Inc., and Careus Corp. for Patent Infringement

    Endonovo Therapeutics, Inc. (ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, filed a patent infringement lawsuit today in the U.S. District Court for the Central District of California against KVP INTERNATIONAL, INC., a California Corporation, ORTHOCOR MEDICAL, INC., a Delaware Corporation, and CAERUS CORP., a Minnesota Corporation. KVP has even trademarked the KVP Cura name it uses to refer to its infringing products and/or product line The KVP Cura line infringes, where according to KVP’s own website, “the KVP Cura line reduces pain and increases blood flow, providing effective therapy for a variety of ailments.

  • GlobeNewswire

    Endonovo Therapeutics Issues Shareholder Letter and Update

    It is with great pleasure that I provide you with an update on Endonovo’s business development initiatives and our recent accomplishments. From a financing perspective, we recently entered into a line of credit at a 6% discount to market to reduce dilution for interim financing.

  • GlobeNewswire

    Endonovo Therapeutics Enters into $10 million Common Stock Purchase Agreement with Azure Capital

    Endonovo Therapeutics, Inc. (ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, announced today it has executed a Common Stock Purchase Agreement (the “Purchase Agreement”) with Azure Capital (“Azure”) to sell up to $10 Million in common stock to Azure over a term of 36 months, commencing after a registration statement related to the transaction has been filed and declared effective by the U.S. Securities and Exchange Commission. Alan Collier, CEO of Endonovo Therapeutics, stated, “We are excited about this partnership with Azure Capital and the opportunity of potential future access to capital at attractive terms.

  • GlobeNewswire

    Endonovo Therapeutics Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office

    LOS ANGELES, CA, Dec. 18, 2018 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™.

  • GlobeNewswire

    Endonovo Expands SofPulse Commercialization

    LOS ANGELES, CA, Dec. 13, 2018 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™.

  • GlobeNewswire

    Endonovo Therapeutics Announces Strategic Relationship with US Authentic Trading Company

    LOS ANGELES, CA, Dec. 03, 2018 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™.

  • GlobeNewswire

    Endonovo Therapeutics Announces Complimentary New Product

    LOS ANGELES, CA, Nov. 08, 2018 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™.